Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK9 | P50750 | 13/20 | 0.45 |
| ▸ | CDK7 | P50613 | 12/20 | 0.45 |
| ▸ | AURKA | O14965 | 1/20 | 0.41 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.41 |
| ▸ | IGF1R | P08069 | 1/20 | 0.41 |
| ▸ | CDK4 | P11802 | 1/20 | 0.41 |
| ▸ | EPHA1 | P21709 | 1/20 | 0.41 |
| ▸ | CDK2 | P24941 | 1/20 | 0.41 |
| ▸ | CDK3 | Q00526 | 1/20 | 0.41 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.41 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.41 |
| ▸ | ALK | Q9UM73 | 3/20 | 0.40 |
| ▸ | SYK | P43405 | 1/20 | 0.39 |
| ▸ | PTK2 | Q05397 | 2/20 | 0.38 |
| ▸ | TTK | P33981 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10128168 | 0.90 | CDK9 (0.56) | CDK9CDK7AURKANTRK1IGF1R | |
| SCHEMBL10128158 | 0.90 | CDK9 (0.49) | CDK9CDK7AURKANTRK1IGF1R | |
| SCHEMBL10128165 | 0.90 | CDK9 (0.56) | CDK9CDK7AURKANTRK1IGF1R | |
| SCHEMBL10128237 | 0.86 | IRAK4 (0.42) | CDK9CDK7AURKANTRK1IGF1R | |
| Hydrochloric Acid SCHEMBL282838 | 0.85 | IRAK4 (0.42) | CDK9CDK7AURKANTRK1IGF1R | |
| SCHEMBL10128201 | 0.84 | SYK (0.55) | CDK9CDK7AURKANTRK1IGF1R | |
| SCHEMBL10128203 | 0.84 | SYK (0.55) | CDK9CDK7AURKANTRK1IGF1R | |
| SCHEMBL10128154 | 0.84 | SYK (0.47) | CDK9CDK7AURKANTRK1IGF1R | |
| SCHEMBL10128187 | 0.84 | SYK (0.45) | CDK9CDK7AURKANTRK1IGF1R | |
| SCHEMBL10128179 | 0.84 | SYK (0.45) | CDK9CDK7AURKANTRK1IGF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9487491-B2 | Diamino heterocyclic carboxamide compound | ASTELLAS PHARMA INC. (JP) | 2016-11-08 | — | — | US | disclosed |
| US-8969336-B2 | Diamino heterocyclic carboxamide compound | ASTELLAS PHARMA INC. (JP) | 2015-03-03 | — | — | US | disclosed |
| US-20140371196-A1 | DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2014-12-18 | — | — | US | disclosed |
| US-20120040968-A1 | DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND | WATERS TECHNOLOGIES CORPORATION (US) | 2012-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140371196-A1 | DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND | EML4, ALK, ERBB4 | CDK9 293/4885CDK7 952/4885AURKA 19/4885 |
| US-20120040968-A1 | DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND | EML4, ALK, ERBB4 | CDK9 293/4885CDK7 952/4885AURKA 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.